Tag Archives: Sanofi-Aventis

Can Sanofi's Expanding Predictive Modeling Technology Enhance the Productivity of R&D?

By William Looney | Published: February 15, 2012
As the hurdles to successful commercialization of new medicines continue to mount, the ability to find and exploit cost efficiencies in the development process has become a critical source of competitive advantage.  This is true not only for biologic drugs but also increasingly for vaccines, now a high growth segment of the medicines business, with [...]
Posted in Biotech | Also tagged , , | Leave a comment

With Botanicals, No Patent, No Expiry, says Sanofi Exec

By Ben Comer | Published: May 20, 2011
What if a new drug could be trademarked instead of patented, keeping generics companies at bay for the life of the trademark, i.e., forever? That was one of the ideas floated to reporters yesterday by Sanofi-Aventis’ Ray Jupp, VP of the fibrosis and wound repair therapeutic strategic unit, an early-stage research division created as part of [...]
Posted in R&D, Strategy | Also tagged , , , , | 3 Comments

Is Sanofi Right to Bank on MS Drug?

By Julian Upton | Published: February 23, 2011
Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath [...]
Posted in Safety, Strategy, pricing | Also tagged , , , , | 1 Comment

Medicines Malaise: Sanofi's Fresh Bet on Patient Centric R&D

By William Looney | Published: January 12, 2011
With a new R&D structure and a high profile appointment to lead it, Sanofi is bidding for leadership in that “new model” the industry is seeking to replenish its anemic pipeline of new products Reinvigorating the productive capacity of in-house R&D is the most prominent strategic challenge confronting big Pharma.  There are many options but few [...]
Posted in R&D, Strategy | Also tagged , | Leave a comment

Genzyme Snubs Sanofi Offer

By George Koroneos | Published: August 31, 2010
Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it. “Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
Posted in Deals | Also tagged , | 1 Comment